- Home
- BNRG vs EDSA Comparison
BNRG vs EDSA Comparison
Compare BNRG & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNRG
- EDSA
- Stock Information
- Founded
- BNRG 2012
- EDSA 2015
- Country
- BNRG Israel
- EDSA Canada
- Employees
- BNRG N/A
- EDSA N/A
- Industry
- BNRG
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- BNRG
- EDSA Health Care
- Exchange
- BNRG Nasdaq
- EDSA Nasdaq
- Market Cap
- BNRG 5.2M
- EDSA 13.8M
- IPO Year
- BNRG 2022
- EDSA N/A
- Fundamental
- Price
- BNRG $2.59
- EDSA $2.03
- Analyst Decision
- BNRG
- EDSA Strong Buy
- Analyst Count
- BNRG 0
- EDSA 2
- Target Price
- BNRG N/A
- EDSA $13.00
- AVG Volume (30 Days)
- BNRG 143.6K
- EDSA 15.1K
- Earning Date
- BNRG 03-04-2025
- EDSA 08-08-2025
- Dividend Yield
- BNRG N/A
- EDSA N/A
- EPS Growth
- BNRG N/A
- EDSA N/A
- EPS
- BNRG N/A
- EDSA N/A
- Revenue
- BNRG N/A
- EDSA N/A
- Revenue This Year
- BNRG N/A
- EDSA N/A
- Revenue Next Year
- BNRG N/A
- EDSA N/A
- P/E Ratio
- BNRG N/A
- EDSA N/A
- Revenue Growth
- BNRG N/A
- EDSA N/A
- 52 Week Low
- BNRG $1.78
- EDSA $1.55
- 52 Week High
- BNRG $15.30
- EDSA $5.59
- Technical
- Relative Strength Index (RSI)
- BNRG 40.62
- EDSA 51.40
- Support Level
- BNRG $2.21
- EDSA $1.91
- Resistance Level
- BNRG $2.73
- EDSA $2.14
- Average True Range (ATR)
- BNRG 0.36
- EDSA 0.12
- MACD
- BNRG 0.05
- EDSA 0.02
- Stochastic Oscillator
- BNRG 39.30
- EDSA 56.67
About BNRG Brenmiller Energy Ltd
Brenmiller Energy Ltd is a technology company that develops, produces, markets, and sells thermal energy storage. The technology of the company allows electrification and decarbonization of the industrial industry sector for integration with renewable energy sources and further reduction of carbon emissions.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.